Abstract:Background & Aims Accumulating evidence has indicated the presence of mature miRNAs in the nucleus, but their effects on steatohepatitis remain elusive. We have previously demonstrated that the intranuclear miR-204-3p in macrophages protects against atherosclerosis, which shares multiple risk factors with metabolic dysfunction-associated steatotic liver disease (MASLD). Herein, we aimed to explore the functional significance of miR-204-3p in steatohepatitis. Methods miR-204-3p levels and subcellular localization were assessed in the livers and peripheral blood mononuclear cells (PBMCs) of MASLD patients. Wild-type mice fed a high-fat diet (HFD) or methionine- and choline-deficient (MCD) diet were administered an adeno-associated virus system containing miR-204-3p to determine the effect of miR-204-3p on steatohepatitis. Co-culture systems were applied to investigate the crosstalk between macrophages and hepatocytes or hepatic stellate cells (HSCs). Multiple high-throughput epigenomic sequencings were performed to explore miR-204-3p targets. Results miR-204-3p expression decreased in the livers and macrophages in mice and patients with fatty liver. In MASLD patients, miR-204-3p levels in PBMCs were inversely related to the severity of hepatic inflammation and damage. Macrophage-specific miR-204-3p overexpression reduced steatohepatitis in HFD- or MCD diet-fed mice. miR-204-3p-overexpressing macrophages inhibited TLR4/JNK signaling and pro-inflammatory cytokine release, thereby limiting fat deposition and inflammation in hepatocytes and fibrogenic activation in HSCs. Epigenomic profiling identified miR-204-3p as a specific regulator of ULK1 expression. ULK1 transcription and VPS34 complex activation by intranuclear miR-204-3p improved autophagic flux, promoting the anti-inflammatory effects of miR-204-3p in macrophages. Conclusions miR-204-3p inhibits macrophage inflammation, coordinating macrophage actions on hepatocytes and HSCs to ameliorate steatohepatitis. Macrophage miR-204-3p may be a therapeutic target for MASLD. Impact and implications Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic inflammatory disease ranging from simple steatosis to non-alcoholic steatohepatitis. However, the molecular mechanisms underlying the progression of MASLD remain incompletely understood. Here, we demonstrate that miR-204-3p levels in circulating peripheral blood mononuclear cells are negatively correlates with disease severity in patients with MASLD. Nuclear miR-204-3p activates ULK1 transcription and improves autophagic flux, limiting macrophage activation and hepatic steatosis. Our study provides a novel understanding of the mechanism of macrophage autophagy and inflammation in steatohepatitis and suggests that miR-204-3p may act as a potential therapeutic target for MASLD.

Mtfp1 ablation enhances mitochondrial respiration and protects against hepatic steatosis

HIF1A-dependent Overexpression of MTFP1 Promotes Lung Squamous Cell Carcinoma Development by Activating the Glycolysis Pathway

Targeting Intestinal Transporter Glut5 to Prevent the High Fructose-Induced Steatotic Liver Disease

Mitochondrial topoisomerase I (Top1MT) prevents the onset of metabolic dysfunction-associated steatohepatitis (MASH) in mice

Mitochondrial Methionyl-tRNA Formyltransferase Deficiency Alleviates Metaflammation by Modulating Mitochondrial Activity in Mice

Hepatic‐specific Pgc‐1α ablation drives fibrosis in a MASH model

MAPK15 Protects Against The Development Of Metabolic Dysfunction-Associated Steatotic Liver Disease

Mettl3-m6A-YTHDF1 axis promotion of mitochondrial dysfunction in metabolic dysfunction-associated steatotic liver disease

Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis

Mitochondrial fission process 1 (MTFP1) controls bioenergetic efficiency and prevents inflammatory cardiomyopathy and heart failure in mice

Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease

Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease

Acetylation of Mitochondrial Trifunctional Protein α-Subunit Enhances Its Stability To Promote Fatty Acid Oxidation and Is Decreased in Nonalcoholic Fatty Liver Disease

Moderate Replacement of Fish Oil with Palmitic Acid-Stimulated Mitochondrial Fusion Promotes Β-Oxidation by Mfn2 Interacting with Cpt1α Via Its GTPase-domain.

Unravelling the role of mitochondrial dysfunction in the switching towards progressive MASLD by exploiting an AMLN diet-fed mouse model

Fatty acid oxidation alleviates the energy deficiency caused by the loss of MPC1 in MPC1+/- mice.

1599-P: Regulation of Mitochondrial Dynamics Ameliorates Hepatic Steatosis through TFEB Activation

Inactivation of mitochondrial MUL1 E3 ubiquitin ligase deregulates mitophagy and prevents diet-induced obesity in mice

Non-alcoholic fatty liver disease in mice with hepatocyte-specific deletion of mitochondrial fission factor

Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice

Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1α